Description:
NSABP B-45 Worksheet for Reporting Initiation of Sunitinib/Placebo Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=61A68212-D8B0-0740-E040-BB89AD431DF9
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=61A68212-D8B0-0740-E040-BB89AD431DF9
Keywords:
Versions (2) ▾
- 8/27/12
- 1/9/15
Uploaded on:
January 9, 2015
DOI:
No DOI assigned. To request one please log in.License:
Creative Commons BY-NC 3.0 LegacyModel comments:
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for:
Item comments for:
In order to download data models you must be logged in. Please log in or register for free.
Breast Cancer NCT00914043 Treatment - NSABP B-45 Worksheet for Reporting Initiation of Sunitinib/Placebo - 2830516v1.0
This paper worksheet may be completed to facilitate the entry of the information in NSABP Coordinator Online. Partially completed forms may be saved in Coordinator Online. DO NOT SUBMIT THIS WORKSHEET VIA FAX OR MAIL. For all patients, information on initiation of Sunitinib/Placebo must be reported within 4 weeks following randomization
- StudyEvent: NSABP B-45 Worksheet for Reporting Initiation of Sunitinib/Placebo